S3840 Dna analysis ret-oncogene
Also known as: RET gene testing, proto-oncogene testing
Deoxyribonucleic acid sequencing and analysis of the RET proto-oncogene for mutations associated with familial medullary thyroid carcinoma.
In Plain Language
genetic test for thyroid cancer risk; medullary thyroid cancer gene test
Clinical Context
Used in medical oncology and endocrinology for screening of families with hereditary medullary thyroid carcinoma.
RVU Information
CPT S3840 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
S-codes are used by private payers (not Medicare) for services without a standard CPT or HCPCS code. Coverage varies significantly between insurers. Verify payer acceptance before billing and document medical necessity thoroughly.
Specialties
Frequently Asked Questions
What is CPT code S3840?
CPT S3840 (Dna analysis ret-oncogene) is a S Codes code. Deoxyribonucleic acid sequencing and analysis of the RET proto-oncogene for mutations associated with familial medullary thyroid carcinoma.
Is S3840 covered by insurance?
S3840 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used in medical oncology and endocrinology for screening of families with hereditary medullary thyroid carcinoma.
When is CPT S3840 used?
Used in medical oncology and endocrinology for screening of families with hereditary medullary thyroid carcinoma.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.